Testing IBI302 for wet age-related macular degeneration
Part of Eyes & vision clinical trials.
This study tests a new medicine called IBI302 for wet age-related macular degeneration (AMD). It aims to slow vision loss by targeting both blood vessel growth and inflammation. You might qualify if you have active wet AMD and have not had certain injections recently.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 50 years or older.
- You have active wet age-related macular degeneration (AMD) with abnormal blood vessels under the center of your retina.
- Your vision in the study eye is between roughly 20/100 and 20/40 (measured on a standard eye chart).
- You have not had anti-VEGF treatment (like Lucentis, Avastin, or Eylea) in the study eye within the last 90 days.
- You have not had anti-complement treatment in the study eye within the last 90 days.
- Your blood pressure and diabetes are under control (HbA1c under 10%).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called SKG0106, given as an injection into the eye, for people with wet age-related macular degeneration (AMD). It aims to see if it is safe and effective in treating the leaky blood vessels that cause vision loss.
This trial tests a new gene therapy called RRG001 for people with the 'wet' form of age-related macular degeneration. It aims to treat leaky blood vessels in the eye that can cause vision loss, possibly reducing the need for frequent eye injections.
This study tests whether a new eye injection called ABP 938 works as well as or better than the current standard treatment (Eylea) for wet age-related macular degeneration—a condition that causes vision loss in the center of your sight. You would receive injections into your eye every month for a year.
This trial tests an investigational drug called SCT520FF for people with wet age-related macular degeneration (nAMD). It aims to find the safest dose and check if it can improve vision. You may be eligible if you have active new blood vessels in your eye from nAMD and have not had certain other eye problems.
This trial tests a new CRISPR-based treatment for wet age-related macular degeneration (AMD). It aims to stop vision loss by targeting the cause of abnormal blood vessel growth in the eye. This study is for people who have already tried anti-VEGF injections but might not be responding well enough.
This trial tests a new treatment called IVB103 for people with wet age-related macular degeneration (AMD). It aims to see if the injection is safe and effective for those who have already had anti-VEGF therapy. You may qualify if you have active disease and have had at least two prior anti-VEGF treatments.
Hear when a new Neovascular Age-related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.